Abstract
SummaryThis article intends to summarize and comment on some of the highlights regarding myelodysplastic syndrome (MDS) presented at the 2022 American Society of Hematology (ASH) annual meeting. Many abstracts dealt with the validation of the two new classifications and the International Prognostic Scoring System–Molecular (IPSS-M) being among the most intensively discussed topics in the community. Moreover, for the first time, real-world data on luspatercept were presented. Long-term data from the MEDALIST trial showed which patients benefit most from therapy with luspatercept, adding important information for the use of this substance. However, except for the phase III trial Sintra-REV, practice-changing clinical reports were sparse, although earlier trials in both higher-and lower-risk MDS reported on promising agents currently in clinical development that will hopefully improve the future management of MDS patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
